Table 3.
Estrogen and aromatase inhibitor levels in breast cancer patients
| Treated with letrozole | Treated with exemestane | |||||
|---|---|---|---|---|---|---|
| LET | E2 | E1 | EXE | 17HEXE | E2 | E1 |
| 290 | 1.2 | 1.5 | 5.1 | 1.2 | 1.1 | 4.1 |
| 193 | <LOQ | 0.5 | 0.8 | 0.4 | <LOQ | 2.4 |
| 252 | <LOQ | 0.4 | 0.6 | 0.3 | <LOQ | 2.3 |
| 238 | <LOQ | 0.3 | 7.0 | 1.0 | <LOQ | 2.3 |
| 361 | <LOQ | <LOQ | 90.2 | 7.0 | <LOQ | 1.7 |
| 349 | <LOQ | <LOQ | 2.0 | 0.5 | <LOQ | 1.5 |
| 326 | <LOQ | <LOQ | 30.1 | 4.7 | <LOQ | 1.4 |
| 245 | <LOQ | <LOQ | 3.3 | 0.7 | <LOQ | 1.1 |
| 329 | <LOQ | <LOQ | 45.4 | 4.7 | <LOQ | 0.6 |
| 372 | <LOQ | <LOQ | 63.2 | 8.4 | <LOQ | 0.5 |
| 869 | <LOQ | <LOQ | 38.7 | 4.9 | <LOQ | 0.4 |
| 262 | <LOQ | <LOQ | 34.1 | 7.9 | <LOQ | 0.4 |
| 241 | <LOQ | <LOQ | 1.8 | 0.6 | <LOQ | 0.3 |
| 269 | <LOQ | <LOQ | 27.4 | 4.5 | <LOQ | 0.3 |
| 263 | <LOQ | <LOQ | 6.1 | 1.4 | <LOQ | <LOQ |
| 323 | <LOQ | <LOQ | Treated with anastrozole | |||
| 275 | <LOQ | <LOQ | ||||
| 290 | <LOQ | <LOQ | ANA | E2 | E1 | |
| 211 | <LOQ | <LOQ | 6.5 | 4.5 | 25.3 | |
| 181 | <LOQ | <LOQ | 109 | 2.3 | 5.5 | |
| 341 | <LOQ | <LOQ | 112 | <LOQ | 2.1 | |
| 376 | <LOQ | <LOQ | 81.6 | <LOQ | 1.2 | |
| 268 | <LOQ | <LOQ | ||||
| 742 | <LOQ | <LOQ | ||||
| 30.4 | <LOQ | <LOQ | ||||
| 251 | <LOQ | <LOQ |
E2 and E1 concentrations pmol/L. LET, ANA, EXE, and 17HEXE are given in nmol/L.
Abbreviations: 17HEXE, 17-hydroxyexemestane; ANA, anastrozole; E1, estrone; E2, estradiol; EXE, exemestane; LET, letrozole; LOQ, limit of quantification.